|
The kinase inhibitor field is maturing. This conference is designed to examine the question of what lays ahead, what is in store for the pharmaceutical industry and what new avenues are opening up be in regards to technologies and methods used or in regards to novel targets and therapeutic approaches explored. What novel kinase indications are “out there”, in addition to cancer as a target, what other therapeutic areas are blossoming?
|